News Agency
The Times

Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

  • Written by PR Newswire

SINGAPORE, Feb. 17, 2023 /PRNewswire/ -- February 16th, 2023, Biosyngen Pte Ltd (hereinafter as "Biosyngen") was granted approval by US FDA for the company's IND application for BRG01 cell therapy, path the way for Phase I/II clinical trial. BRG01 is an autologous T cell therapy for relapsed/metastatic nasopharyngeal cancer (NPC) treatment....

Read more: Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against...

How Does Temporary Fencing Help Simplify Project Planning?

Why Does Temporary Fencing Matter During Project Planning?  A controlled boundary is essential when construction, infrastructure maintenance, demolition,  landscaping, and other projects are underway. That is when temporary fencing becomes an important  option to consider. The fencing layout affects more than site... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion